Dr Sandor Kantor


I joined the laboratory of Professor Jenny Morton in the spring of 2011 where my main efforts have been directed towards identifying the sleep and EEG abnormalities in Huntington’s disease (HD). Using R6/2 mice, a transgenic model of HD with a progressive neurological phenotype, I have been studying the changes in EEG and sleep-wake architecture in these mice at different stages of the disease. In the course of these studies, I became interested in whether environmental or pharmacological manipulations could restore sleep-wake and EEG patterns in HD mice.

Research Focus


Huntington's disease





Clinical conditions

Genetic disorders

Huntington's disease

Sleep disorders


Behavioural analysis

Electroencephalography (EEG)

Electrophysiological recording techniques



Tom Scammell Web: https://sleep.med.harvard.edu/people/...

Associated News Items



    Kantor S, Varga J, Morton AJ (2016), “A single dose of hypnotic corrects sleep and EEG abnormalities in symptomatic Huntington's disease mice.” Neuropharmacology 105: 298-307


    Haller J, Aliczki M, Pelczer KG, Spitzer K, Balogh Z, Kantor S (2014), “Effects of the fatty acid amide hydrolase inhibitor URB597 on coping behavior under challenging conditions in mice.” Psychopharmacology (Berl) 231(3):593-601 Details


    Kantor S, Mochizuki T, Lops SN, Ko B, Clain E, Clark E, Yamamoto M, Scammell TE (2013), “Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice.” Sleep 36(8):1129-38 Details

    Kantor S, Szabo L, Varga J, Cuesta M, Morton AJ (2013), “Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation.” Brain 136(Pt 7):2147-58 Details


    Kantor S, Mochizuki T, Janisiewicz AM, Clark E, Nishino S, Scammell TE (2009), “Orexin neurons are necessary for the circadian control of REM sleep.” Sleep 32(9):1127-34 Details


    Gyongyosi N, Balogh B, Kirilly E, Kitka T, Kantor S, Bagdy G (2008), “MDMA treatment 6 months earlier attenuates the effects of CP-94,253, a 5-HT1B receptor agonist, on motor control but not sleep inhibition.” Brain Res 1231:34-46 Details

    Kirilly E, Molnar E, Balogh B, Kantor S, Hansson SR, Palkovits M, Bagdy G (2008), “Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days.” Int J Neuropsychopharmacol 11(6):795-809 Details


    Kantor S, Jakus R, Molnar E, Gyongyosi N, Toth A, Detari L, Bagdy G (2005), “Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram power spectra.” J Pharmacol Exp Ther 315(2):921-30 Details


    Balogh B, Molnar E, Jakus R, Quate L, Olverman HJ, Kelly PA, Kantor S, Bagdy G (2004), “Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.” Psychopharmacology (Berl) 173(3-4):296-309 Details

    Graf M, Jakus R, Kantor S, Levay G, Bagdy G (2004), “Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy.” Neurosci Lett 359(1-2):45-8 Details

    Jakus R, Graf M, Ando RD, Balogh B, Gacsalyi I, Levay G, Kantor S, Bagdy G (2004), “Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy.” Brain Res 1008(2):236-44 Details

    Kantor S, Jakus R, Balogh B, Benko A, Bagdy G (2004), “Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505.” Br J Pharmacol 142(8):1332-42 Details


    Graf M, Kantor S, Anheuer ZE, Modos EA, Bagdy G (2003), “m-CPP-induced self-grooming is mediated by 5-HT2C receptors.” Behav Brain Res 142(1-2):175-9 Details


    Kantor S, Jakus R, Bodizs R, Halasz P, Bagdy G (2002), “Acute and long-term effects of the 5-HT2 receptor antagonist ritanserin on EEG power spectra, motor activity, and sleep: changes at the light-dark phase shift.” Brain Res 943(1):105-11 Details


    Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S (2001), “Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635.” Int J Neuropsychopharmacol 4(4):399-408 Details

    Bódizs R, Kántor S, Szabó G, Szûcs A, Erõss L, Halász P (2001), “Rhythmic hippocampal slow oscillation characterizes REM sleep in humans.” Hippocampus 11(6):747-53 Details

    Filakovszky J, Kantor S, Halasz P, Bagdy G (2001), “8-OH-DPAT and MK-801 affect epileptic activity independently of vigilance.” Neurochem Int 38(7):551-6 Details

    Kantor S, Graf M, Anheuer ZE, Bagdy G (2001), “Rapid desensitization of 5-HT(1A) receptors in Fawn-Hooded rats after chronic fluoxetine treatment.” Eur Neuropsychopharmacol 11(1):15-24 Details


    Kantor S, Anheuer ZE, Bagdy G (2000), “High social anxiety and low aggression in Fawn-Hooded rats.” Physiol Behav 71(5):551-7 Details